|
Tuesday 29 May
|
| 14:00-18:00 |
Registration at the Conference Venue |
|
|
|
|
| 18:30-21:30 |
Opening ceremony, welcome reception and dinner |
|
|
|
|
|
Wednesday 30 May
|
| 08:00-08:45 |
Registration |
|
|
|
|
| 08:45-09:00 |
Welcome and Introduction |
|
|
|
|
| 09:00-10:10 |
Model-based dose individualisation – biomarker focus |
Chair:Chantal Csajka, Nick Holford
|
| 09:00-09:20 |
Thierry Buclin |
Meeting clinicians' and patients' needs in the practice of therapeutic monitoring |
| 09:20-09:50 |
Catherine Sherwin |
Model-based dose individualization approaches using biomarkers |
| 09:50-10:10 |
Ron Keizer |
Experiences in applied clinical pharmacometrics: challenges, recommendations, and research opportunities |
|
|
|
|
| 10:10-11:40 |
Coffee break, Poster and Software session I |
|
Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter |
|
|
|
|
| 11:40-12:20 |
Model-based dose individualisation – biomarker focus, continued |
Chair: Chantal Csajka, Nick Holford
|
| 11:40-12:00 |
Maddalena Centanni |
A pharmacometric framework for dose individualisation of sunitinib in GIST |
| 12:00-12:20 |
Chloé Pasin |
Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients |
|
|
|
|
| 12:20-13:00 |
Estimands |
Chair:France Mentré
|
| 12:20-12:35 |
Mouna Akacha |
Background on estimands and why are they important? |
| 12:35-12:50 |
Mick Looby |
PMX perspective on estimands |
| 12:50-13:00 |
|
Discussion on estimands |
|
|
|
|
|
| 13:00-14:30 |
Lunch |
|
|
|
|
| 14:30-15:50 |
Stuart Beal Methodology Session |
Chair:Justin Wilkins
|
| 14:30-14:50 |
Camille Vong |
Power assessment for hierarchical combination endpoints using joint modelling of repeated time-to-event and time-to-event models versus Finkelstein-Schoenfeld method |
| 14:50-15:10 |
Yixuan Zou |
A novel score test-based method for efficient covariate selection in population pharmacokinetic analysis |
| 15:10-15:30 |
Qing Xi Ooi |
Evaluation of assumptions underpinning pharmacometric models |
| 15:30-15:50 |
Mats Karlsson |
Extensive and automatic assumption assessment of pharmacometric models |
|
|
|
|
| 15:50-17:20 |
Tea break, Poster and Software session II |
|
Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter |
|
|
|
|
| 17:20-17:40 |
Clinical applications |
Chair:Marylore Chenel
|
| 17:20-17:40 |
Oskar Alskär |
An integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with Type 2 diabetes |
|
|
|
|
| 17:40-18:00 |
Pharmacoeconomics |
Chair: Marylore Chenel
|
| 17:40-18:00 |
Daniel Hill-McManus |
Application of a linked pharmacometric/pharmacoeconomic model to assess the impact of non-adherence: Application to the treatment of gout |
|
|
|
|
|
|
|
|
|
Thursday 31 May
|
| 08:30-09:55 |
Lewis Sheiner Student Session |
Chair: Julie Bertrand, Alain Munafo, Ana Ruiz
|
| 08:30-08:50 |
Simon Buatois |
A pharmacometric extension of MCP-MOD in dose finding studies |
| 08:50-09:10 |
Benjamin Guiastrennec |
New dosing recommendations for anti-tuberculosis therapy in Indian children |
| 09:10-09:30 |
Jurgen Langenhorst |
Cause-specific hazard models with Markovian elements to quantify the fludarabine exposure-response relationship: from learning to confirming in allogeneic hematopoietic cell transplantation |
| 09:30-09:50 |
Gustaf Wellhagen |
A bounded integer model for rating and composite scale data |
| 09.50-09.55 |
Presentation of Lewis Sheiner student session awards |
|
|
|
|
| 09:55-11:30 |
Coffee break, Poster and Software session III |
|
Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter |
|
|
|
|
| 11:30-12:30 |
Oncology
|
Chair:Lena Friberg
|
| 11:30-11:50 |
Phyllis Chan |
Assessment of a model to correlate early tumor size response to overall survival in relapsed or refractory diffuse large B cell lymphoma patients |
| 11:50-12:10 |
Rui Zhu |
Exposure-response (E-R)-based product-profile (PP)-driven clinical utility index (CUI) to support phase III dose selection in oncology |
| 12:10-12:30 |
Zinnia Parra-Guillen |
A quantitative modelling framework to inform dose selection of Xentuzumab, a dual insulin-like growth factor-I/II neutralizing antibody in cancer patients |
|
|
|
|
| 12:30-12:35 |
Announcement for ACoP9 (2018) |
CJ Musante
|
|
|
|
|
| 12:35-14:10 |
Lunch |
|
|
|
|
| 14:10-15:10 |
Immuno-oncology |
Chair:Dinesh de Alwis, Pascal Girard
|
| 14:10-14:40 |
Scott K Pruitt |
Clinical overview of immunotherapy in oncology |
| 14:40-15:10 |
Benjamin Ribba |
Drug response variability and optimal dosing in immuno-oncology |
|
|
|
|
| 15:10-16:40 |
Tea break, Poster and Software session IV |
|
Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter |
|
|
|
|
| 16:40-17:20 |
Immuno-oncology, continued |
Chair:Dinesh de Alwis, Pascal Girard
|
| 16:40-17:00 |
Rukmini Kumar |
Predicting response and identifying responders to combination cancer immunotherapy in melanoma using Quantitative Systems Pharmacology (QSP) models |
| 17:00-17:20 |
Hanna Silber Baumann |
PKPD analysis of soluble CD25 to characterize the concentration-effect relationship observed following the administration of Cergutuzumab Amunaleukin, a targeted immunocytokine for cancer immunotherapy |
|
|
|
|
| 17:20-17:25 |
Announcement for WCoP2020 |
Stacey Tannenbaum
|
|
|
|
|
| 18:30-01:30 |
Social event |
|
|
|
|
|
Friday 1 June
|
| 09:15-09:55 |
Clinical Applications |
Chair:Marylore Chenel
|
| 09:15-09:35 |
David Ternant |
Population and Bayesian kinetic modelling of necrosis biomarkers to assess the effect of conditioning therapies on infarct size |
| 09:35-09:55 |
João Abrantes |
Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia A patients using a full random effects modelling approach (FREM) |
|
|
|
|
| 09:55-10:35 |
Systems pharmacology |
Chair: Charlotte Kloft
|
| 09:55-10:15 |
Chihiro Hasegawa |
Simplification of multi-scale systems models for data-driven analyses: what has progressed in these 5 years? |
| 10:15-10:35 |
Elin Boger |
A partial differential equation approach to inhalation PBPK modelling |
|
|
|
|
| 10:35-10:40 |
Preview of PAGE 2019 |
|
|
|
|
| 10:40-11:20 |
Coffee break and Software session |
|
|
|
|
| 11:20-11:30 |
DDMoRe Model Repository challenge – prize ceremony |
Chair:Thomas Dorlo, Céline Sarr
|
|
|
|
|
| 11:30-12:10 |
Antivirals |
Chair: Thomas Dorlo
|
| 11:30-11:50 |
Sulav Duwal |
A multiscale mechanistic framework to predict drug-class specific prophylactic efficacy of antiviral drugs against HIV |
| 11:50-12:10 |
Vincent Madelain |
Ebola viral dynamics in nonhuman primates: insights into virus immuno-pathogenesis and antiviral strategies |
|
|
|
|
| 12.10-12.20 |
Closing remarks |
|
|
|
|
| 12:20-12:35 |
Audience input for potential PAGE2019 topics |
